---
title: "Lenacapavir: A Breakthrough in HIV Prevention with 100% Efficacy"
description: "Lenacapavir: A Breakthrough in HIV Prevention with 100% Efficacy"
image: https://image.informedainews.com/2024/06/Hea-a3d-1718936607-0.jpg
---


:::info

"Informed AI News" is a news aggregation platform based on AI, aiming to provide users with high-quality news content that has been carefully selected and organized. It analyzes a vast array of news sources, filtering out low-quality or untrustworthy information to ensure that users receive accurate and timely news.  [Find out more >>](/)

:::

# Lenacapavir: A Breakthrough in HIV Prevention with 100% Efficacy

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">
<img
  src="https://image.informedainews.com/2024/06/Hea-a3d-1718936607-0.jpg"
  alt="Lenacapavir: A Breakthrough in HIV Prevention with 100% Efficacy"
/>



In a pivotal trial, biopharmaceutical giant Gilead Sciences announced that its new drug, Lenacapavir, effectively prevented HIV infection with a 100% success rate among 2134 women. This drug, administered via a twice-yearly injection, contrasts with daily oral medications currently in use.

Trial Details and Impact

The "PURPOSE 1" study, conducted across South Africa and Uganda, randomized participants into groups receiving Lenacapavir, Descovy, or Truvada. The group receiving Lenacapavir reported zero infections, while the others saw infection rates of 1.69 and 2.02 per 100 individuals, respectively.

Significance and Market Response

Gilead's Chief Medical Officer, Merdad Parsey, emphasized Lenacapavir's potential as a game-changer in HIV prevention. The convenience of a bi-annual injection could significantly improve adherence and accessibility, especially for high-risk populations.

The market reacted positively, with Gilead's stock rising 8.46% following the announcement, increasing its market value by nearly $67 billion. Analysts forecast peak sales could reach $20 billion, reflecting high expectations for the drug's future impact.

Looking Ahead

Gilead plans to confirm these results in ongoing trials, specifically targeting men who have sex with men. If successful, Lenacapavir could be approved for PrEP by late 2025, providing a revolutionary tool in the worldwide battle against HIV.

This breakthrough not only represents a significant advancement in medical science but also highlights the evolving approach to HIV prevention, shifting towards more convenient and effective methods.
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 5    | Content provides balanced reporting on the trial results and market impact.    |
	| Social Impact | 6     | Significant impact on public opinion and potential policy changes in HIV prevention.    |
	| Credibility    | 5    | Solid evidence from a large-scale trial by a reputable pharmaceutical company.    |
	| Potential    | 5    | High potential to trigger significant changes in HIV prevention strategies.    |
	| Practicality    | 4    | Highly practical with potential for direct application in healthcare.    |
	| Entertainment Value    | 2    | Some interest due to breakthrough in medical science, but primarily informative.    |
</TabItem>
</Tabs>

[Full article>>](https://wallstreetcn.com/articles/3717741)
